Solstein Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Solstein Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-67	Closed	-$30.4K	–	516
2025 Q4	$30.4K	Hold	67	–	–	0.01%	250
2025 Q3	$26.2K	Sell	67 -22	-25%	-$9.19K	0.01%	253
2025 Q2	$39.6K	Buy	+89	New	+$41K	0.02%	219
2021 Q3	–	Sell	-35	Closed	-$7K	–	508
2021 Q2	$7K	Hold	35	–	–	0.01%	365
2021 Q1	$8K	Buy	+35	New	+$7.69K	0.01%	314
2020 Q1	–	Sell	-83	Closed	-$18K	–	383
2019 Q4	$18K	Buy	+83	New	+$16.8K	0.04%	205

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Solstein Capital's VRTX Position: Q1 2026 in Review

Solstein Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 67 shares — an estimated $30.4K sold.

Solstein Capital first reported a position in VRTX in Q4 2019 and held it in 6 quarters. The position peaked at $39.6K in Q2 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Solstein Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Solstein Capital sold 67 Vertex Pharmaceuticals shares in Q1 2026, an estimated $30.4K.
Solstein Capital first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Solstein Capital's Vertex Pharmaceuticals position peaked at $39.6K in Q2 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.